Wavice (KOSDAQ: 289930), South Korea's only fully vertically integrated maker of gallium nitride (GaN) radio-frequency (RF) semiconductors, swung to an operating profit on an annual basis in 2025 for the first time in its history, but has since fallen back into losses. The Korea Investor Relations Service (KIRS) Corporate Research Centre published an AI-generated company analysis report on Wavice on 4th September, examining its financial performance and business structure.
Wavice is unique among South Korean firms in having internalised the entire value chain of RF power-amplification technology — from bare GaN RF semiconductor chips and packaged transistors through to finished modules. It was spun off from telecoms components maker Giga-Lane in 2017, having won a GaN RF power-amplification device process-development contract from the Agency for Defence Development (ADD) in 2015, through which it completed a 0.4-micrometre, 150-watt power-amplification process technology. The company listed on the KOSDAQ technology-growth segment in October 2024.
Its annual financial trajectory had been one of steady improvement. Revenue rose from 16.9bn won in 2023 to 29.4bn won in 2024 (up 74.0%), and further to 40.7bn won in 2025 (up 38.5%). Operating losses narrowed from 9.5bn won in 2023 to 4.9bn won in 2024, before turning to a 600m won profit in 2025 — the company's first annual operating surplus since its founding.
The first half of 2026, however, has brought a reversal. According to a half-year report disclosed on 13th August, revenue for the January–June period fell 11.0% year on year to 12.9bn won, against 14.5bn won a year earlier, while the operating loss widened to 4.1bn won. Although that represents a 16.8% narrowing compared with the 4.9bn won operating loss recorded in the same period of 2025, the second quarter in isolation was more troubling: the cost of sales rose to 12.1bn won from 11.2bn won a year earlier, leaving gross profit at a thin 800m won. Write-downs on inventory also ballooned from 700m won to 1.8bn won year on year. Net profit for the half-year came in at 45.1bn won, but this figure reflects gains on financial asset revaluations and should not be read as an indicator of underlying cash-generating ability.
Customer concentration poses another risk that investors should heed. In the first half of 2026, a single client — designated "Company A" in the filing, believed to be a defence-systems integrator — accounted for 10bn won, or 77.64% of total revenue. The company's results are therefore highly sensitive to any shift in that customer's order volumes.
The strategic significance of Wavice's capabilities is most clearly visible through the lens of supply-chain security. Virtually every country in the world currently relies entirely on a handful of American and Japanese suppliers for GaN chips, and both the United States and Japan classify GaN RF semiconductors as strategic components subject to export-licence controls. This has created difficulties even in the maintenance of weapons systems developed using foreign-sourced chips. Based on public disclosures, Wavice is the only South Korean company to have brought GaN RF semiconductor production to a mass-manufacturing stage domestically.
On the order book, two contracts are in the process of being fulfilled: a 26.5bn won initial-production supply agreement with Hanwha Systems for multi-function radar (MFR) high-power amplifier boards for the L-SAM long-range surface-to-air missile system, and a 13bn won production contract for MFR systems destined for the fourth batch of Ulsan-class frigates (hull 41-2). Both provide a degree of revenue visibility, though defence procurement contracts carry inherent risks of delivery delays and scope changes.
The contrast with the closest domestic peer is stark. RFHIC (KOSDAQ: 218410) posted consolidated revenue of 185.8bn won and operating profit of 30.9bn won in 2025, an operating margin of 16.6% — dwarfing Wavice's 40.7bn won in revenue and 1.5% operating margin. On valuation, Wavice trades at a price-to-earnings ratio of 58.5 times, well above RFHIC's 30.2 times, suggesting that a great deal of growth optimism is already priced in. In the first half of 2026, RFHIC's revenue grew 23.6% year on year to 94.6bn won, while Wavice's contracted by 11.0%.
The company's stated growth initiatives include expansion into the Indian market, the construction of a new factory in Cheonan on land acquired for roughly 6.7bn won, and the addition of contract manufacturing for medical devices (specifically, a neural-examination instrument). The medical device business is targeting GMP facility certification by the second quarter of 2027, with the intention of using existing cleanroom infrastructure to spread fixed costs while opening up a new revenue stream.
Dilution risk also looms. Wavice has outstanding bonds with warrants (the seventh series, with a face value of 33.5bn won) that carry the right to subscribe for up to 3,855,005 new shares. That potential issuance represents roughly 30% of the current share count of 13 million, creating latent downward pressure on the share price.
The stock peaked at 23,800 won on 27th April 2026 — its 52-week high — before falling sharply to 6,750 won as of 27th August, a decline of 60.0% over six months. That compares with a 26.4% fall in the KOSDAQ index over the same period, meaning Wavice has underperformed the benchmark by more than 33 percentage points. Its market capitalisation now stands at approximately 89bn won.